Identifying Circulating Exosomes as a Biomarker in Glioma

Article
Conference|American Association for Cancer Research Annual Meeting (AACR)

In this video, Michael Ciesielski, PhD, of Roswell Park Cancer Institute in Buffalo, talks about circulating exosomes isolated from the serum of malignant glioma patients enrolled in a completed phase I clinical trial of an anti-survivin vaccine (SurVaxM).

Dr. Ciesielski presented a study on how specific exosomes appear to be associated with early tumor progression in recurrent malignant glioma patients at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Recent Videos
Related Content
Data from the phase 2b ReNeu trial may support mirdametinib as a valuable new treatment option for adults and children with NF1-PN.

Mirdametinib Yields Significant Responses and HRQOL Improvements in NF1-PN

Russ Conroy
November 14th 2024
Article

Data from the phase 2b ReNeu trial may support mirdametinib as a valuable new treatment option for adults and children with NF1-PN.

The Stand Up 2 Cancer Colorectal Dream Team

The Stand Up 2 Cancer Colorectal Dream Team

Luis A. Diaz, Jr., MD
May 10th 2018
Podcast

During AACR 2018, Dr. Diaz discusses the progress of his laboratory’s colorectal cancer research as part of the Stand Up 2 Cancer Colorectal Dream Team.

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Gina Mauro
April 15th 2024
Article

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

Uncovering Epigenetic Targets in Cancer

Uncovering Epigenetic Targets in Cancer

Stephen Baylin, MD
April 11th 2018
Podcast

Dr. Stephen Baylin discusses his 2018 AACR meeting presentation on SU2C research into using epigenetic therapy to boost immune checkpoint therapy.

Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC

Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC

Courtney Flaherty
April 13th 2024
Article

A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.

Investigators also look to assess linvoseltamab in relapsed/refractory multiple myeloma as part of the phase 3 LINKER-MM3 trial.

Linvoseltamab Shows Responses, Safety in Relapsed/Refractory Myeloma

Kristi Rosa
April 10th 2024
Article

Investigators also look to assess linvoseltamab in relapsed/refractory multiple myeloma as part of the phase 3 LINKER-MM3 trial.